Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of "Deutsche Studiengruppe Multiples Myelom".

被引：0
|
作者：
Gerecke, Christian [1 ]
Knop, Stefan [2 ]
Topp, Max S. [2 ]
Liebisch, Peter [3 ]
Vollmuth, Christina [2 ]
Platzbecker, Uwe [4 ]
Maeder, Uwe [5 ]
Einsele, Hermann [6 ]
Bargou, Ralf C. [2 ]
机构：
[1] Helios Hosp Berlin Buch, Berlin, Germany
[2] Univ Wurzburg, Med Ctr, Wurzburg, Germany
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[4] Univ Hosp Dresden, Dresden, Germany
[5] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[6] Univ Wurzburg, Dept Hematol Oncol, Wurzburg, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：961 / 961
页数：1
相关论文
共 50 条
  • [1] The efficacy and toxicity of the RAD regimen (Revlimid®, Adriamycin® Dexamethasone) in relapsed and refractory multiple myeloma -: A phase I/II trial of "Deutsche Studiengruppe Multiples Myelom"
    Knop, Stefan
    Gerecke, Christian
    Liebisch, Peter
    Topp, Max S.
    Hess, Georg
    Platzbecker, Uwe
    Frohnert, Sandra
    Einsele, Hermann
    Bargou, Ralf
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [2] RESULTS OF A PHASE I/II TRIAL OF DEUTSCHE STUDIENGRUPPE MULTIPLES MYELOM, SHOWING EFFICACY AND SAFETY OF RAD REGIMEN (REVLIMID®, ADRIAMYCIN®, DEXAMETHASONE) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Knop, S.
    Gerecke, C.
    Liebisch, P.
    Topp, M. S.
    Platzbecker, U.
    Vollmuth, C.
    Einsele, H.
    Bargou, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 256 - 256
  • [3] Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
    Knop, Stefan
    Gerecke, Christian
    Liebisch, Peter
    Topp, Max S.
    Platzbecker, Uwe
    Sezer, Orhan
    Vollmuth, Christina
    Falk, Karina
    Glasmacher, Axel
    Maeder, Uwe
    Einsele, Hermann
    Bargou, Ralf C.
    BLOOD, 2009, 113 (18) : 4137 - 4143
  • [4] Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Popat, Uday R.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Champlin, Richard E.
    Weber, Donna M.
    BLOOD, 2012, 120 (21)
  • [5] A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Morphey, Ashley
    Johnson, Ralph J.
    Wesson, Emily T.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Weber, Donna M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : E319 - E322
  • [6] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [7] Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma -: First results of a german multicenter phase I/II trial.
    Knop, Stefan
    Gerecke, Christian
    Topp, Max S.
    Liebisch, Peter
    Hess, Georg
    Kotkiewitz, Sandra
    Einsele, Hermann
    Bargou, Ralf
    BLOOD, 2006, 108 (11) : 125A - 125A
  • [8] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [9] Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Alexanian, Raymond
    Wang, Michael
    Thomas, Sheeba
    Qazilbash, Muzaffar H.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday
    Weber, Donna
    BLOOD, 2010, 116 (21) : 811 - 812
  • [10] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
    Lunning, Matthew Alexander
    Ruan, Jia
    Nair, Sumithra
    Boruchov, Adam M.
    Byrne, Regina
    Gerecitano, John F.
    Hamlin, Paul A.
    Inserra, Beth
    Leonard, John
    Lynch, Peggy
    Matasar, Matthew J.
    Moskowitz, Alison J.
    Moskowitz, Craig
    Myskowski, Patricia L.
    Nolan, Patrick
    Palomba, Maria Lia
    Quefeld, Christiane
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345